Author:
Kane John M.,Crandall David T.,Marcus Ronald N.,Eudicone James,Pikalov Andrei,Carson William H.,Swyzen Wim
Subject
Biological Psychiatry,Psychiatry and Mental health
Reference28 articles.
1. Remission in schizophrenia: proposed criteria and rationale for consensus;Andreasen;Am. J. Psychiatry,2005
2. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80, and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study;Arato;Int. Clin. Psychopharmacol.,2002
3. Factors influencing relapse in the long-term course of schizophrenia;Ayuso-Gutiérrez;Schizophr. Res.,1997
4. Olanzapine relapse prevention study group. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse;Beasley;J. Clin. Psychopharmacol.,2003
5. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors;Burris;J. Pharmacol. Exp. Ther.,2002
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献